X2S1 Stock Overview
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$13.30 |
| 52 Week High | HK$13.50 |
| 52 Week Low | HK$9.15 |
| Beta | 0.85 |
| 1 Month Change | 7.26% |
| 3 Month Change | 16.67% |
| 1 Year Change | 17.70% |
| 3 Year Change | 44.57% |
| 5 Year Change | n/a |
| Change since IPO | 36.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| X2S1 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 3.1% | -0.2% | -0.3% |
| 1Y | 17.7% | 16.5% | 7.0% |
Return vs Industry: X2S1 exceeded the German Healthcare industry which returned 16.5% over the past year.
Return vs Market: X2S1 exceeded the German Market which returned 7% over the past year.
Price Volatility
| X2S1 volatility | |
|---|---|
| X2S1 Average Weekly Movement | 6.2% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X2S1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: X2S1's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 113,635 | Wanyong Lian | www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
| X2S1 fundamental statistics | |
|---|---|
| Market cap | €8.47b |
| Earnings (TTM) | €1.14b |
| Revenue (TTM) | €77.72b |
7.4x
P/E Ratio0.1x
P/S RatioIs X2S1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X2S1 income statement (TTM) | |
|---|---|
| Revenue | CN¥590.35b |
| Cost of Revenue | CN¥543.16b |
| Gross Profit | CN¥47.18b |
| Other Expenses | CN¥38.53b |
| Earnings | CN¥8.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.77 |
| Gross Margin | 7.99% |
| Net Profit Margin | 1.47% |
| Debt/Equity Ratio | 78.1% |
How did X2S1 perform over the long term?
See historical performance and comparisonDividends
4.2%
Current Dividend Yield31%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 23:11 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinopharm Group Co. Ltd. is covered by 43 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Mann | Barclays |
| Derrick Sun | BNP Paribas Securities (Asia) |
| Bo Li | BofA Global Research |